Published in Int J Tuberc Lung Dis on November 01, 1999
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother (2010) 1.45
Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets. PLoS One (2014) 0.83
Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis. J Orthop Surg Res (2014) 0.77
Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. BMC Infect Dis (2016) 0.75
Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial. PLoS One (2016) 0.75
Preparation, in vitro characterization, and in vivo pharmacokinetic evaluation of respirable porous microparticles containing rifampicin. Sci Pharm (2014) 0.75
Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. Antimicrob Agents Chemother (2015) 0.75
Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicrob Agents Chemother (1997) 1.99
Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther (2003) 1.64
Respiratory tuberculosis in childhood: the diagnostic value of clinical features and special investigations. Pediatr Infect Dis J (1995) 1.51
Clofazimine: current status and future prospects. J Antimicrob Chemother (2011) 1.41
Universal pattern of RpoB gene mutations among multidrug-resistant isolates of Mycobacterium tuberculosis complex from Africa. Int J Tuberc Lung Dis (1999) 1.39
Activity of 7-methyljuglone derivatives against Mycobacterium tuberculosis and as subversive substrates for mycothiol disulfide reductase. Bioorg Med Chem (2007) 1.15
Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother (2007) 1.09
Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis (1999) 1.03
Childhood tuberculosis and tuberculous meningitis: high incidence rates in the Western Cape of South Africa. Tuber Lung Dis (1992) 1.02
Follow-up tuberculosis prevalence survey of Transkei. Tubercle (1980) 0.96
Mycobacterium bovis as a zoonosis in the Kruger National Park, South Africa. Int J Tuberc Lung Dis (1999) 0.93
A population study on rheumatoid arthritis in Lesotho, southern Africa. Ann Rheum Dis (1986) 0.93
Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med (1996) 0.92
Evaluation of a rapid test for HIV antibodies in saliva and blood. S Afr Med J (2000) 0.92
Antimicrobial activity of clofazimine is not dependent on mycobacterial C-type phospholipases. J Antimicrob Chemother (2004) 0.89
The near future: improving the activity of rifamycins and pyrazinamide. Tuberculosis (Edinb) (2010) 0.89
Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis. Phytomedicine (2006) 0.88
Next-generation sequencing for identifying pyrazinamide resistance in Mycobacterium tuberculosis. Clin Infect Dis (2013) 0.84
Tuberculosis prevalence survey in the Daveyton (Benoni) urban black community. S Afr Med J (1981) 0.80
Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis. Int J Tuberc Lung Dis (2004) 0.80
BCG vaccination and the EPI. S Afr Med J (1987) 0.80
The life-span of mammals: estimates for the dassie (Procavia capensis) J S Afr Vet Assoc (1978) 0.79
The prevalence and annual rate of tuberculous infection in South Africa. Tubercle (1983) 0.78
The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations. Int J Tuberc Lung Dis (2001) 0.78
Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs. Int J Tuberc Lung Dis (2007) 0.77
Mycobacterium tuberculosis in a closed colony of baboons (Papio ursinus). Lab Anim (1983) 0.77
Adjunctive therapy with bromocriptine in Parkinson's disease. S Afr Med J (1990) 0.76
Tuberculosis control in South Africa--time for a new paradigm? S Afr Med J (1996) 0.75
The colorimetric analysis of anti-tuberculosis fixed-dose combination tablets and capsules. Int J Tuberc Lung Dis (1999) 0.75
Tuberculosis in laboratory animals. J S Afr Vet Assoc (1978) 0.75
The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability. Int J Tuberc Lung Dis (1999) 0.75
Correction for Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. Mol Pharm (2015) 0.75
Ethical issues in epidemiological research. S Afr Med J (1987) 0.75
Patterns of tuberculin hypersensitivity in South Africa. Tubercle (1983) 0.75
The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency. Int J Tuberc Lung Dis (1999) 0.75
Notification of tuberculosis. S Afr Med J (1986) 0.75
A surface impression and scanning electron microscopic study of porokeratosis of Mibelli. Br J Dermatol (1977) 0.75
Intravenous immunoglobulin prophylaxis in neonates on artificial ventilation. S Afr Med J (1996) 0.75